Piramal Pharma (PPLPHARMA)

STALWART

FairStock Score: 20/100 — RISKY

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Current Price₹163.8
Market Cap₹20,753.55 Cr
P/E Ratio0
ROCE6.45%
ROE-2.01%
Dividend Yield0.09%
Profit Growth-3,241.3%
Debt/Equity0.6
Sales Growth-0.87%
Free Cash Flow₹40,400 Cr
Promoter Holding34.85%
52-Week Range₹132.3 — ₹220.85
SectorPharmaceuticals & Biotechnology
Book Value₹61.13

Piramal Pharma trades with ROCE of 6.45%, ROE of -2.01%, profit growth of -3,241.3%, debt-to-equity of 0.6. The FairStock Score of 20/100 flags concerns across multiple fundamental dimensions that investors should examine carefully.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer